or Try an Advanced Search...

    Technical Analysis for ZVSA - ZyVersa Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.61 8.41% 0.05
    ZVSA closed up 8.41 percent on Wednesday, April 24, 2024, on 11 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ZVSA trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction 8.41%
    Narrow Range Bar Range Contraction 8.41%
    Lower Bollinger Band Walk Weakness 8.41%
    Wide Bands Range Expansion 8.41%
    Down 3 Days in a Row Weakness 8.41%
    Oversold Stochastic Weakness 8.41%
    Older End-of-Day Signals for ZVSA ...

       Recent Intraday Alerts

    Alert Time
    Up 10% about 20 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    Rose Above Previous Day's High about 24 hours ago
    Up 5% about 24 hours ago
    Up 3% about 24 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ZVSA Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address high unmet medical needs in the areas of renal and inflammatory diseases. ZyVersa's development pipeline includes phase 2a ready VAR 200, a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has potential to treat other glomerular diseases, including Alport syndrome and diabetic kidney disease. ZyVersa's development pipeline also includes IC 100, a novel inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Organ Systems Kidney Disease Inflammatory Diseases Kidney Diabetic Nephropathy Alport Syndrome Diabetic Kidney Disease Focal Segmental Glomerulosclerosis Glomerulosclerosis Inflammasome Stage Specialty Biopharmaceutical

    Is ZVSA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 4 ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
    Mar 25 ZyVersa Therapeutics GAAP EPS of -$0.29
    Mar 25 ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
    Mar 18 ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
    Mar 14 ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
    Feb 29 ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
    Feb 28 ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
    Feb 26 Microcap ZyVersa up 71% on study supporting new way to fight obesity
    Feb 22 ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
    Feb 14 ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
    See more ZVSA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.085
    52 Week Low 0.5
    Average Volume 2,967,960
    200-Day Moving Average 2.83
    50-Day Moving Average 0.76
    20-Day Moving Average 0.68
    10-Day Moving Average 0.62
    Average True Range 0.08
    RSI (14) 40.48
    ADX 28.32
    +DI 28.83
    -DI 20.92
    Chandelier Exit (Long, 3 ATRs) 0.61
    Chandelier Exit (Short, 3 ATRs) 0.78
    Upper Bollinger Bands 0.83
    Lower Bollinger Band 0.53
    Percent B (%b) 0.26
    BandWidth 43.07
    MACD Line -0.06
    MACD Signal Line -0.05
    MACD Histogram -0.0093
    Fundamentals Value
    Market Cap 1 Million
    Num Shares 1.64 Million
    EPS -78.43
    Price-to-Earnings (P/E) Ratio -0.01
    Price-to-Sales 0.00
    Price-to-Book 0.05
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.68
    Resistance 3 (R3) 0.67 0.65 0.67
    Resistance 2 (R2) 0.65 0.63 0.65 0.66
    Resistance 1 (R1) 0.63 0.62 0.64 0.63 0.66
    Pivot Point 0.60 0.60 0.61 0.60 0.60
    Support 1 (S1) 0.58 0.58 0.59 0.59 0.56
    Support 2 (S2) 0.56 0.57 0.56 0.56
    Support 3 (S3) 0.54 0.56 0.55
    Support 4 (S4) 0.54